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Amyloid probes based on Congo Red distinguish between fibrils 
comprising different peptides 
Ted T Ashburn*+, Hogyu Han*, Brian F  McGuinness* and Peter T  Lansbury, Jr 
Background: Amyloid plaques, which characterize degenerating tissue in 
Alzheimer’s disease (brain) and type ii diabetes (pancreas), were first visualized 
by staining with the dye Congo Red (CR). The ability of CR to recognize amyloid 
fibrils comprising diverse proteins suggests that the binding site includes an 
unidentified structural feature common to all amyloid fibrils. We set out to design 
and synthesize analogs of CR that could distinguish between fibrils comprising 
different peptides. 
Results: Relative affinities of several CR analogs for two model amyloid fibrils 
were measured and compared to that of CR. Amyloid fibrils comprising peptides 
based on the critical carboxyl terminus of the Alzheimer’s disease amyloid protein 
pl-42 (p34-42) and the critical region of the type II diabetes pancreatic 
amyloid protein, IAPP (IAPP20-29) were tested. The ratio of affinities of each 
individual CR analog for the two amyloid fibrils varied considerably. 
Complexation of certain metal ions (Cu(ll), iIn( Ni(ll), Cd(ll)) by a CR analog 
did not abolish its affinity for amyloid but changed the affinity ratio significantly. 
Conclusions: This study demonstrates that small organic and organometallic 
molecules are capable of detecting differences in amyloid fibril structure and/or 
amyloid protein sequence. Molecules of this type could have utility as 
neuropathological probes or imaging agents, since they are much easier to 
prepare and functionalize than antibodies and are specific for the fibrillar form of 
the amyloid proteins. 
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Introduction 
Alzheimer’s disease (AD) was originally described, and is 
still diagnosed, based on the presence in the 
postmortem brain of proteinaceous deposits, known as 
amyloid plaques, that stain with the dye Congo Red 
(CR) [1,2]. Amyloid deposition is still the primary 
neuropathological criterion for the diagnosis of AD ([3]; 
the method described in this reference is one of many 
based on plaque density). Amyloid plaques contain a 
core of ordered fibrillar protein aggregates. In the case of 
AD, the predominant brain amyloid proteins are pl-42 
and its carboxy-terminal truncated relative pl-40 [l] 
(Fig. 1). The carboxy-terminal sequence determines the 
rate of amyloid formation; pl-42 aggregates much more 
rapidly in vitro than pl-40 [4]. Monoclonal antibodies 
that distinguish pl-40 and pl-42 have been used to 
show that pl-42 is more prominent in the blood serum 
(Younkin, S.G., unpublished data) and in the 
postmortem brain [.5] of patients with two classes of 
early-onset AD (caused by point mutations in a 
presenilin protein (chromosome 14) or in the amyloid 
precursor protein (chromosome 21)) relative to patients 
with late-onset disease. The peptide p34-42 has been 
studied as a model of the critical region of @ l-42 
amyloid 16-91. Amyloid fibrils formed in vitro from 
p34-42 fibrils resemble naturally derived AD amyloid 
fibrils at the ultrastructural level, and the peptide fibrils 
produce a similar, yet more highly resolved, X-ray 
diffraction pattern [6]. The peptide fibrils in vitro and 
the native AD fibrils in brain sections both stain in a 
birefringent manner with Congo Red [6]. It is not yet 
possible, however, to determine if @34-42 and the 
carboxy-terminal region of the pl-42 amyloid fibrils are 
structurally identical [9,10]. 
Recently, a second protein component of the fibrillar 
plaque core has been described, called NAC (the non-AP 
component of AD amyloid) Ill]. Although it is only a 
minor plaque component at the time of death (-10 %  of 
total amyloid protein), NAC may trigger the pathogenic 
cascade by seeding amyloid formation by fil-40 [12]. 
Despite all of the convergent suggestive evidence, it is 
important to note that amyloidogenesis has not been 
proven to be a cause of AD neurodegeneration [1,13]. 
The major obstacle towards clarifying the relationship 
between amyloid deposition and neurodegeneration is 
that it is not currently possible to non-invasively monitor 
the deposition of brain amyloid. A long-term goal of the 
work described here is to develop new imaging agents 
that allow the comparison of the deposition of amyloid 
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Figure 1 
pl-42 H2N-~AEFRHDSGYEVHHQKLVFFAEDVGSNKGA,,~~MVGGVV~-CO*H 
p1-40 H2N-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAl lGLMVGGVV-CO2H 
p34-42 H2N-LMVGGVVIA-C02H 
IAPP H2N-IkNTATCATQRLANFLVHS:NNFGALS~TNVGSNT:CONH2 
IAPP20-29 AcHN-SNNFGALSSCONH2 
The sequences of pl -42, /31-40, IAPP and 
corresponding model peptides p34-42 and 
IAPP20-29. 
over time (possibly distinguishing between different 
amyloid proteins) with the appearance of AD symptoms. 
Other diseases are also characterized by tissue degener- 
ation at the site of amyloid deposition. Type II (non 
insulin-dependent, slow-onset) diabetes is characterized 
by pancreatic amyloid deposits comprising the 37-amino- 
acid islet amyloid polypeptide (IAPP, also known as 
amylin, Fig. 1) [14]. Type II diabetes does not occur in 
rodents, which may be due to sequence variations between 
human and rat IAPP that seem to prevent amyloid 
formation by the rat protein. A synthetic peptide derived 
from human IAPP (IAPPZO-29) forms amyloid fibrils that 
resemble those formed from full-length IAPP with respect 
to their ultrastructural dimensions, X-ray diffraction 
pattern and staining properties [15]. The peptide model of 
rat IAPP (amino acids 20-29) does not form fibrils, 
consistent with the behavior of the rat protein [16-191. As 
is the case in AD, a causal relationship between amyloid 
libril formation and disease has not been established [ 141. 
To rationally design molecules that bind amyloid more 
tightly than CR or distinguish between amyloid fibrils 
comprising different proteins, a structure of the amyloid 
fibril ‘receptor’ or, even better, of the CR-fibril complex 
must be determined. The ordered nature of binding is 
indicated by the fact that amyloid stained with CR 
exhibits green birefringence when observed using a 
polarizing light microscope [ZO]. More detailed structural 
information is difficult to obtain, since amyloid fibrils are 
insoluble and noncrystalline [9,10]. Infrared spectroscopy 
and X-ray diffraction analysis of many amyloid fibrils 
indicate that they all have a subunit antiparallel l3 sheet 
[lo]. It has been suggested that this structure represents 
the CR recognition element, and a crude model of the 
CR-amyloid complex, characterized by intercalation of 
CR between the hydrophobic amyloid sheets, has been 
proposed [20-Z]. An alternative electrostatic model for 
binding of CR to an idealized antiparallel p sheet has 
been proposed [23,24]. Solid-state NMR studies of 
p34-42 and IAPPZO-29 amyloid fibrils show that, 
although the P-sheet structures of both amyloids may be 
unusually compacted, they differ significantly in detail 
[7,9,10,17,19]. Thus a variety of CR-binding modes may 
exist. The only detailed structural information regarding 
a CR-protein complex is a crystal structure of a complex 
of CR with a soluble, globular insulin dimer [ZS]. This 
CR binding mode may not resemble that with an 
insoluble, non-crystalline amyloid fibril. 
In the absence of structural data, a systematic and 
quantitative structure-activity study of the features of the 
CR molecule that lead to amyloid binding would be useful. 
Very little information of this type exists. The binding of 
CR to two amyloid fibrils, comprising insulin [23,24] or 
another peptide model of AD brain amyloid @1043), has 
been quantified [26,27]. Furthermore, the affinity of several 
CR analogs and related aromatic dyes to l310-43 amyloid 
fibrils has been indirectly measured [26,27]. Based on this 
information, a crude model of the CR-amyloid complex, 
featuring electrostatic interactions between the CR 
sulfonate groups and regularly spaced cationic groups at the 
amyloid surface has been proposed [26]. This model is not 
applicable to all amyloid fibrils, as the p34-42 fibril (see 
below) binds CR but contains no charged side chains. 
Here, we describe the relative affinity of a series of CR 
analogs for two model amyloid fibrils (p34-42 and 
IAPPZO-29) (Figs l-3 and Table 1). We have chosen to 
work with peptide models, rather than full-length proteins 
or naturally-derived material, because the peptides have 
been extensively characterized, making it possible to 
eventually describe binding at the molecular level. The 
results suggest that certain features of CR are important for 
amyloid fibril binding and reveal that the binding affinity 
is strongly dependent on the constitution of the amyloid 
fibril. The latter finding suggests that it may be possible to 
design small molecule probes that distinguish amyloid 
fibrils based on their constitution and/or morphology. Such 
probes may be useful in developing in viva diagnostic 
agents for diseases characterized by amyloid deposition. 
Results and discussion 
Synthesis of CR analogs with a modified biphenyl group 
A series of CR analogs (Fig. 2, compounds 2-10) was 
designed to replace the biphenyl group of CR with related 
functional groups in which the preferred biphenyl dihedral 
angle was altered (compounds 2, 3, 4, 6) or where the 
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Figure 2 
NaOsS’ 1 ‘SOsNa 
4=&3- H3C 
3 H* 
CH3 
5 q-- 
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9 CuW3 
10 Cd@)2 
The structures of CR analogs generated by modification of the central 
biphenyl group (solid box) and chelation of metals by the bipyridyl 
analog 6. 
naphthyl to naphthyl distance was shortened (compound 
5). Compound 4 is the only one of this group whose 
synthesis has not been reported previously. These 
compounds were prepared by a route used for synthesis of 
CR, replacing the biphenyl4,4’-diamine intermediate with 
analogous diamines [Z&-31]. The commercially available 
analog 3,3’-dimethyl-CR (benzopurpurin 4B) 3 was 
intended as a control for 2,2’-dimethyl-CR 2, as the hydro- 
phobicity of these compounds was expected to be similar. 
The biphenyl dihedral angle of 3, however, was expected 
to be closer to that of CR than the dihedral of compound 2, 
which is significantly perturbed relative to CR. 
Preparation of metal complexes of the 
bipyridyl-containing analog 6 
To explore the possibility that CR analogs could be used to 
direct metals to amyloid, which may eventually enable us 
to image amyloid formation in vivo, metal complexation by 
bipyridyl-CR 6 was investigated (Fig. ‘2). Metal complexes 
were prepared by addition of metal salts to aqueous 
solutions of compound 6. Complexation was followed and 
the stoichiometry was determined by UV/visible 
spectroscopy (Fig. 4). Zinc (complex 7), nickel (complex 
8), cadmium (complex lo), and cobalt (not shown) formed 
complexes with a stoichiometry of one metal ion per two 
molecules of compound 6 (Fig. 2). Copper formed a com- 
plex with a 1:3 stoichiometry (Fig. 2, complex 9). 
Synthesis of CR analogs with modified naphthyl groups 
A series of CR analogs were designed to probe the impor- 
tance of the naphthyl groups for binding to amyloid (Fig. 
3, compounds 11-15). Direct Violet 43 (compound 11) 
Figure 3 
SOsNa 
11 
NaO,S’ 
13 
14 NaW 
15 
The structures of the CR analogs used in this study generated by 
modification of the CR terminal naphthyl groups (dotted box). 
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has the naphthyl amino group replaced by a phenolic 
hydroxyl group [31]. The commercially available dyes 
Evans Blue (compound 12) and Trypan Blue (com- 
pound 13) were also tested, and Direct Blue 6 (com- 
pound 14) an analog of compound 13, was synthesized 
[31]. Finally, compound 15, which represents half of the 
symmetric CR molecule, was also synthesized [32,33]. 
CR binds to 834-42 and IAPP20-29 amyloid fibrils with 
comparable affinity 
To conveniently measure the K, of a given compound 
directly, a radiolabeled analog of each compound had to be 
synthesized. Since this was not practical for each analog 
used in this study, a displacement binding assay was 
devised in order to measure the relative affinities of each 
CR analog for the model amyloid fibrils B34-42 and 
IAPPZO-29. 35S-labeled CR was equilibrated with j334.X 
or IAPPZO-29 amyloid fibrils under conditions where 
-85 %  of the dye was bound. Increasing concentrations of 
unlabeled compounds were added, until 50 %  of the 
bound 35S-labeled CR (DC,,) was displaced from the 
fibrils (Fig. 5). For certain compounds, the solubility under 
the assay conditions was less than the DC,,. In these cases, 
DC,, was estimated by extrapolation. The DC,, values for 
CR itself were determined by this method to be 8 (*3) p,M 
for B34-42 and 9 (+3) p,M for IAPPZO-29 (Table 1). We 
describe the relative affinities for the two fibrils as a ratio 
(DC,, for IAPPZO-29/DC,, for B34-42). The affinity ratio 
for CR is therefore 1.1 (Table 1). This finding is consistent 
with the fact that CR recognizes a structural feature 
common to both fibrils. Based on a single experiment,we 
estimate that the K, of CR for B34-42 fibrils is 900 nM. 
The biphenyl-replacement analogs have a range of 
affinities for both p34-42 and IAPP20-29 fibrils 
None of the purely organic CR analogs bound to the CR 
binding site of B34-42 or IAPPZO-29 amyloid more tightly 
than CR itself (Table 1). The affinity ratios varied signifi- 
cantly, however. The analogs designed to test the impor- 
tance of the biphenyl dihedral angle bound slightly less 
well to both peptide fibrils than did CR, but the flat analog 
4 and the orthogonal analog 2 had comparable affinities, 
suggesting that a slightly twisted biphenyl dihedral angle, 
present in CR but unreachable by 2 and 4, may be ideal for 
binding. The bipyridyl CR analog 6 had comparable affin- 
ities to compound 4, possibly due to its reduced hydropho- 
bicity relative to CR. The affinity of compound 3 for both 
peptide fibrils was reduced 30- to 70-fold compared to CR, 
suggesting that hindrance of the naphthyl amine groups by 
the methyl groups may reduce affinity. The truncated 
analog 5 had significantly reduced affinity, which may be 
due to the disposition of the naphthyl binding sites on the 
fibril [26] or the decreased hydrophobicity of 5 relative to 
CR. The affinity ratios for this group of analogs varied from 
3.7 for compound 2, which strongly prefers B342, to 0.69 
for compound 6, which prefers IAPP’ZO-29. 
Metal-bipyridyl-CR complexes bind both amyloids with an 
affinity comparable to that of CR 
Four of the metal complexes of bipyridyl-CR 6 were 
relatively tight binders to the peptide fibrils, in particular 
the cadmium complex 10, which was the only compound 
analyzed herein which bound more tightly than CR. 
Complexes 7 and 8 bound IAPPZO-29 fibrils more tightly 
than B34-42 fibrils, whereas complex 10 bound B34-42 
fibrils more tightly (Table 1). The cobalt complex of 6 did 
not bind tightly to either peptide fibril (DC,, > 120 p,M), 
possibly due to its aggregation at high concentration. The 
affinity ratios for the metal complexes ranged from 2.3 for 
compound 10, which prefers B34-42, to -0.6 for compounds 
Figure 4 
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Bipyridyl-CR (compound 6) binds zinc with a stoichiometry of 2:i and 
copper with a stoichiometry of 3:l. The absorption spectra upon 
titration of compound 6 (21.8 PM) with (a) ZnCI, and (b) CuCI, are 
shown. Metal ions were added in 1 P M  increments. Analyses of the 
binding isotherm from data taken at 514 nm (0) and 610 nm (O), and 
at 514 nm (0) and 568 nm(0) are shown in the insert panels in (a) 
and (b), respectively. The ratios of bipyridyl-CR to ZnCI, and to CuCI, 
are 2:l and 3:1, respectively. 
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Figure 5 
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The binding affinities of CR analogs for peptide fibrils as determined by 
measurement of the displacement of 35S-iabeled CR. The 
displacement profiles for (a) 2,2’-dimethyl-CR (compound 2) (b) 
Zn(6)s (compound 7) and (c) Cd(6), (compound 10) using 20 ~.LM 
634-42 (0) and IAPP20-29 (0) fibrils are shown. The DC,, is the 
concentration of analog required to displace 50 % of the bound CR. 
Note the difference in the scales of the X axes. 
Table 1 
DC,, values (JLM) for displacement of %-labeled CR from 
p34-42 and IAPP20-29 amyloid fibrils with CR and analogs 
Compound 634-42 
1 (CR) 8c 
IAPP20-29 Affinity ratio 
9c 1.1 
2 23= 83a 3.7 
3 229b 623b 2.8 
4 13a 20a 1.5 
5 119b 243= 2.0 
6 1 9.6b 13.5a 0.69 
7 17.0b 9.7b 0.57 
8 1 5.8b 1 0.6b 0.67 
9 20.3a 23.0b 1.1 
10 1.5b 3.5b 2.3 
11 76= 93c 1.2 
12 107c 203a 1.9 
13 62c 238b 3.8 
14 42b 1 23b 2.9 
15 >4000 >4000 
Errors (standard deviations) on each of these values were less than 
al 0 %, bl O-20 % or c20-40 %. The fourth column reports the ratios 
of column three to column two, that is, the relative affinities for 
IAPP20-29 compared to 634-42. A ratio of greater than 1 indicates 
tighter binding to 634-42, a ratio of less than 1 indicates tighter 
binding to IAPP20-29. The raw data for compounds 2, 7 and 10 are 
presented in Figure 5. 
7 and 8, which prefer IAPPZO-29. Complex 9, like CR 
itself, showed little preference. The fact that metal 
complexes retained their affinity for amyloid inspired the 
synthesis of a technetium complex of compound 6, which 
could be useful for SPECT imaging [34]. 
The naphthyl replacement analogs bind less avidly than CR 
and with altered selectivity 
The CR analogs with modified naphthyl groups bound 
to both peptide fibrils with lower affinity than CR and 
most of the biphenyl-replacement analogs. The low 
affinity of phenolic CR 11 supports the observation that 
the amine group (see analog 3) is important in the form- 
ation of the CR-amyloid complex. Puchtler et al. [Z] 
reported that Trypan Blue (compound 13) is less 
effective than CR in staining amyloid fibrils. We 
confirmed this finding with B34-42 and IAPPZO-29 
fibrils. Trypan Blue, however, binds to B34-42 fibrils 
over three-fold more avidly than to fibrils comprising 
IAPPZO-29 (affinity ratio = 3.8). Compound 15 did not 
displace CR from either fibril (DC,, > 4 mM). 
Significance 
In vivo amyloid imaging could determine whether 
amyloid deposition precedes the appearance of 
symptoms and is, therefore, a possible cause of AD, or 
whether amyloid deposition follows the appearance of 
symptoms, being merely a correlated epiphenomenon. 
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In the former case, amyloid imaging could be used to 
diagnose AD. It is also of interest to determine 
whether the various brain amyloid proteins are 
deposited in a specific sequence, as would be expected 
if one particular protein acts as the seed for amyloid 
fibril formation. A small-molecule probe that, like CR, 
specifically recognizes the fibrillar amyloid protein and, 
unlike CR, is specific for one type of amyloid and 
crosses the blood-brain barrier, would be required for 
in vivo imaging. The studies presented here provide a 
first step towards development of such a molecule. 
The rational design of amyloid probes requires an 
understanding of the CR-amyloid interaction at the 
molecular level. Our original goal was to determine the 
features of the CR molecule that confer affinity for 
amyloid and to use this information to design more 
sensitive and specific amyloid probes. The initial 
assumption that all amyloid fibrils share a common CR- 
binding site led to the expectation that the effect of a CR 
modification on amyloid affinity would not depend on 
the composition of the fibril. The data presented here 
clearly show that this assumption is not true. Thus, in 
addition to the general affinity of CR and analogs for all 
amyloid fibrils, there seems to be some specificity for the 
particular peptide comprising the fibril. It is thus 
possible to find CR analogs that distinguish amyloid 
librils of different composition, for example, the brain 
amyloid proteins pl-40 and NAC. Analogs of this 
type could be useful in determining the timing of 
amyloidogenesis by these two proteins in the AD brain. 
Finally, an unexpected finding of these studies was that 
metal binding by a bipyridyl-containing CR analog did 
not drastically reduce its affinity for amyloid, but altered 
its affinity ratio for the two amyloids analyzed. This 
finding suggests the possibility of using metal-CR 
complexes for the purpose of selective imaging of 
amyloid deposits. 
Materials and methods 
General 
‘H-NMR spectra were recorded with a Varian XL-300 NMR spectro- 
meter (300 MHz) in CDsOD unless otherwise specified. Chemical shifts 
are reported in parts per mill ion downfield from tetramethylsilane and 
coupling constants are reported in Hertz. Mass spectra were recorded 
using matrix-assisted laser desorption ionization (MALDI) mass 
spectrometry at the MIT Mass Spectrometty Facility unless otherwise 
specified. The basic peptide tyrosine protein kinase substrate (TPKS, 
[MH]+ = 1593.74) was used for MALDI analysis of the CR analogs [35]. 
Preparative HPLC was performed on a Waters PrepLC 4000 System 
usinga Cl 6 reversed-phase column (30 x 300 mm,  15 km particle size, 
300-A pore size, YMC, Wilmington, NC) with H,O and CHsOH as 
eluents at a flow rate of 50 ml  min-‘. Analytical HPLC was performed on 
a Waters 600E System using a Delta-Pak Cl 8 reversed-phase column 
(3.9 x 300 mm,  15-brn particle size, 300-A pore size, Waters, Milford, 
MA)  with H,O and CHsOH as eluents at a flow rate of 3 ml  min-‘. UV 
spectra were measured on a Hewlett-Packard 8452A diode array 
spectrophotometer. Extinction coefficients (E) reported in cm-‘*M-l were 
measured in buffer (10 m M  NaH,PO,, pH adjusted to 7.4 with 
1 N NaOH) unless otherwise specified. CR was purchased from Fluka. 
3,3’-Dimethyl-CR (Benzopurpurin 4B), Evans Blue, and Trypan Blue were 
purchased from Aldrich. These dyes were purified using preparative 
HPLC before use. 2,2’-Dimethyl-CR (compound 2) [28,29], phenyl-CR 
(compound 5) 1301, bipyridyl-CR (compound 6) (311, Direct Violet 43 
(compound 11) 1311, Direct Blue 6 (compound 14) [31], and truncated 
CR (compound 15) (32,331 were synthesized by published procedures. 
35S-labeled CR was synthesized as described [36]. p34-42 and 
IAPP20-29 were prepared by methods reported previously (6,181. Peptide 
concentrations were determined by quantitative amino acid analysis. 
General synthetic procedure, applied to 2,2’-dimethyl-CR 
(compound 2) 
To a solution of 2,2’-dimethylbenzidine dihydrochloride (199.0 mg, 
0.7 mmol)  in 10 %  HCI (2 ml) at -5 “C was added NaNO, (106 mg, 
1.54 mmol)  in H,O (500 ~1). After 5 min, the resulting yellow solution 
was added dropwise to 4-amino-l -naphthalenesulfonic acid sodium 
salt (360 mg, 1.47 mmol)  and sodium acetate trihydrate (762 mg, 
5.6 mmol)  in H,O (6 ml) at -5 “C. A  distinct color change was 
immediately observed. The reaction was allowed to proceed for at least 
1 h and the product was purified by preparative HPLC. Typical yields 
were -25 %. Purity of the compound was judged to be > 98 %  by 
analytical HPLC and ‘H NMR. The other CR derivatives were synth- 
esized using a similar procedure with the appropriate substitution of 
starting materials [15]. Sodium carbonate replaced sodium acetate for 
the synthesis of Direct Violet 43 (compound 11) and Direct Blue 6 
(compound 14). Preparative HPLC; O-5 min 25 %  CHsOH, 5-20 min 
25-100 %  CHsOH. Analytical HPLC; O-5 min 25 4/o CHsOH, 
5-20 min 25-l 00 o/o CHsOH, b = 46.5 ml. ‘H NMR 6 8.69 (d, J= 8.3, 
2H), 8.64 (s, 2H), 8.26 (d, J= 8.3, 2H), 7.84 (s, 2H), 7.81 (d, J= 8.3, 
2H), Z63 (t, h 8.3, 2H), Z47 (t, J= 8.3, 2H), Z24 (d, J= 8.3, 2H), 2.25 
(s, 6H); m/z for C,,H,,N,O,S,, calc’d 680.8, found 680.6; UV A,, 472 
(E = 1.58 x 1 04), 322 (E = 2.34 x 1 04). 
Fluorenyl-CR (compound 4) 
Preparative HPLC; O-5 min 25 %  CHsOH, 5-20 min 25-1000/o 
CHsOH. Analytical HPLC; O-5 min 250/, CHsOH, 5-20 min 
25-100 o/o CHsOH, R, = 49.5 ml. ‘H NMR 6 8.74 (d, J= 8.4, 2H), 
8.61 (s, 2H), 8.20 (d, J= 8.4, 2H), 8.06 (s, 2H), 7.94 (s, 4H), 7.57 (t, 
J= 8.4, 2H), 7.46 (t, J=8.4, 2H), 4.10 (s, 2H); m/z for C,,H,,N,O,S,, 
calc’d 664.7, found 665.0; UV A,, 498 (E = 2.28 x 1 04). 
Phenyl-CR (compound 5) 
Preparative HPLC; 15 %  CH,OH isocratic. Analytical HPLC; 20% 
CHsOH isocratic, R, = 10.5 ml. ‘H NMR (DMSO-d,J 6 8.73 (d, J= 8.2, 
2H), 8.46 (d, J= 8.2, 2H), 8.30 (s, 2H), 8.13 (s, 4H), Z81 (brs, 4H), 759 
(t, J = 8.2, 2H), 7.49 (t, J = 8.2, 2H); m/z for C,,H,,N,O,S,, calc’d 
576.6, found 576.2; UV X,, 522 (E = 1.64 x 104), 336 (E = 1.21 x 1 04). 
Direct Violet 43 (compound 11) 
Preparative HPLC; O-25 min 30-45 %  CHsOH. Analytical HPLC; 
O-5 min 25 %  CHsOH, 5-20 min 25-l 00 o/o CHsOH, S, = 25.5 ml. 
‘H NMR (500 MHz, DMSO-d,) S  8.45 (d, J = 8.5, 2H), 8.35 (d, 
J= 8.5, 2H), 8.30 (s, 2H), 7.80 (d, J= 8.5, 4H), 7.76 (d, J= 8.5, 4H), 
7.36 (t, J = 8.5, 2H), 7.22 (t, J = 8.5, 2H); m/z for C32H22N40sS2, 
calc’d 654.7, found 654.0; UV X,, 538 (E = 2.39 x 1 04). 
Direct Blue 6 (compound 14) 
Preparative HPLC; O-l 5 min 1 O-40 %  CHsOH. Analytical HPLC; 
O-5 min 5 %  CHsOH, 5-25 min 5-25 o/, CHsOH, R, = 24.0 ml. 
‘H NMR 6 7.71 (d, J= 8.8, 4H), 7.64 (d, J= 8.8, 4H), 7.50 (s, 2H), 
7.12 (d, J= 1.5, 2H), 7.10 (d, J = 1.5, 2H); m/z for C32H24N60,4S4, 
calc’d 844.8, found 844.3; UV A,, 582 (E = 4.54 x 1 04). 
Truncated CR (compound 15) 
Preparative HPLC; O-6 min 15 %  CHsOH, 6-l 0 min 15-80 %  
CHsOH. Analytical HPLC; 10 %  CHsOH isocratic, 5. = 27 ml. ‘H NMR 
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(DMSO-d& 6 8.72 (d, J=9.0, lH), 8.44 (d, J=9.0, lH), 8.28 (s, lH), 
7.96 (d, J= 7.9, 2H), 7.72 (s, 2H), 7.61-7.38 (m, 5H); High-resolution MS 
(positive-ion FAB) for C,,H,,N,O,S [M + 2Hl+, calc’d 329.0834, found 
329.0830; UV h,,. 456 (E = 9.9 x  1 03), 312 (E = 2.0 x  1 03). 
Measurement of affinity for p34-42 and IAPP20-29 amyloids 
Aggregated peptides were prepared by stirring supersaturated 
solutions of peptide (400 p,M) in buffer (100 mM NaH,PO,, 0.2 O/o 
NaN,, pH adjusted to 7.4 with 1 N NaOH) for 2 h. To 35S-labeled CR 
(1 PM) and a varying concentration of the CR analog was added an 
aggregated peptide solution (50 ~1) that remained stirring while 
aliquots were taken. The solutions were diluted to 1 ml with buffer, 
briefly vortexed and equilibrated at room temperature for 30 min 
(20 pM final peptide concentration). Equilibration times greater than 
30 min did not show any change in the amount of CR bound. The 
solutions were then briefly vortexed and filtered through 13 mm extra- 
thick glass fiber filters (Gelman, Ann Arbor, MI) held in 13 mm ‘Pop- 
Top’ filter holders (Nuclepore; Pleasanton, CA). No significant 
decrease in the concentration of CR was observed after CR solutions 
were filtered in the absence of fibrils. The amount of 35S-labeled CR 
bound ([B]) to fibrils was obtained by measuring the radioactivity of the 
filters and by calculation using the equation [Bl = [T] - [Fl where [Fl is 
the concentration of 35S-labeled CR in filtrate (i.e., amount unbound or 
free) and m  is the total amount of 35S-labeled CR added (m = 1 p,M). 
The concentration of CR analogs required to competitively decrease 
the fraction of 35S-labeled CR bound to fibrils by 50 o/, was defined as 
the DC,, value (Fig. 5). Lower DC,, values mean stronger binding and 
vice versa. Each DC,, value is an average of at least three separate 
experiments and each data point in each experiment was performed in 
triplicate. CR binding was dependent on ionic strength of the solution; 
the percentage of CR bound to fibrils derived from 834-42 and 
IAPP20-29 increased with increasing sodium chloride concentration 
(data not shown). 
Determination of metal complex stoichiometries for bipyridyl-CR 
The stoichiometry of the metal complexes was determined from 
titrations performed under saturating conditions (Kd << [bipyridyl-CR]) 
where the stoichiometry of the complex was reflected by the number 
of equivalents of metal ions needed to reach saturation 1371. Metal 
titrations were performed in a 1 cm path-length quartz cuvette with 
bipyridyl-CR solutions (-20 PM) in buffer (10 mM NaH,PO,, pH 7.4) 
at 25 “C. Spectra over the wavelength range 190-820 nm were 
collected after each addition of metal ions (ZnCI,, NiCI,*GH,O, 
CoCI,*GH,O, CuCI,*2H,O, or CdCI,*2.5H,O) in 1 p,M increments 
followed by equilibration with stirring for at least 30 min (Fig. 4). Upon 
addition of metal ions to bipyridyl-CR 6, the absorptions at 344 and 
514 nm decreased in intensity with the concomitant appearance of 
two new absorptions at -390 and 610 nm. Bipyridyl-CR:metal 
stoichiometry determined at A,,, ; Zn(ll) (2:l ratio, 610 nm, Fig. 4a), 
Ni(ll) (2:1, 592 nm), Cu(ll) (3:1, 568 nm, Fig. 4b), Cd(ll) (2:1, 
606 nm), Co(ll) (2:1, 608 nm). 
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